Clinical PET/CT imaging: Promises and misconceptions

NuklearMedizin

Volumn 44, Issue 5 A SUPPL. 1, 2005, Pages

  Czernin, Johannes ^a   Auerbach, M A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Diagnostic accuracy; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE; IMATINIB;

BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; EQUIPMENT DESIGN; GASTROINTESTINAL STROMAL TUMOR; HEAD CANCER; HUMAN; LUNG CANCER; LYMPHOMA; NECK CANCER; PROGNOSIS; REVIEW;

EID: 27644471574     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625210     Document Type: Review

References (45)

1. Beyer T, Townsend D, Brun T et al. A combined PET/CT scanner for clinical oncology. J Nuc Med 2000; 41: 1369-79.
2. Charron M, Beyer T, Bohnen N et al. Image analysis in patients with cancer studied with a combined PET and CT scanner. Clin Nucl Med 2000; 25: 905-10.
3. 13N-ammonia and reoriented dynamic positron emission tomographic imaging. Circulation 1992; 86: 1004-17.
4. Huang S, Phelps M, Hoffman E et al. Error sensitivity of the fluorodeoxyglucose method for measurement of cerebral metabolic rate of glucose. Cereb Blood Flow of Metabol 1981; 1: 391-401.
5. Weber W, Ziegler S, Thodtmann R et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40: 1771-7.
6. Goerres G, Kamel E, Heidelberg T et al. PET-CT image co-registration in the thorax: Influence of respiration. J Nucl Med 2002; 29: 351-60.
7. Beyer T, Antoch G, Blodgett T et al. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003; 30: 588-96.
8. Jemal A, Clegg L, Ward E et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004; 101: 3-27.
9. Halpern BS, Dahlbom M, Auerbach MA et al. Optimizing imaging protocols for overweight and obese patients: A lutetium orthosilicate PET/CT study. J Nucl Med 2005; 46: 603-7.
10. Halpern B, Dahlbom M, Quon A et al. Impact of patient weight and emission scan duration on PET/CT image quality and lesion detectability. J Nucl Med 2004; 45: 797-801.
11. Townsend DW. From 3-D positron emission tomography to 3-D positron emission tomography/computed tomography: what did we learn? Mol Imaging Biol 2004; 6: 275-90.
12. Schaefer NG, Hany TF, Taverna C et al. Non-Hodgkin lymphoma and Hodgkin disease: Coregistered FDG PET and CT at staging and restaging - Do we need contrast-enhanced CT? Radiology 2004; 232: 823-9.
13. 18F-FDG PET/CT. J Nucl Med 2004; 45: 56S-65S.
14. 18F-FDG PET/CT. J Nucl Med 2005; 46: 429-35.
15. Yau Y-Y, Chan W-S, Tam Y-M et al. Application of intravenous contrast in PET/CT: Does it really introduce significant attenuation correction error? J Nucl Med 2005; 46: 283-91.
16. Hany T, Steinert H, Goerres G et al. PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 2002; 225: 575-81.
17. 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube current. Eur J Nucl Med Mol Imaging 2002; 29: 346-50.
18. Allen-Auerbach M, Yeom K, Park J et al. Standard PET/CT chest image acquisition during shallow breathing is inadequate for comprehensive staging of the lung in cancer patients. J Nucl Med 2005; Supplement.
19. Gambhir S, Czernin J, Schwimmer J et al. A tabulated summary of the FDG-PET literature. J Nuc Med 2001; 42: 1S-71S.
20. 18F-FDG uptake: incidence, localization patterns, and clinical significance. J Nucl Med 2005; 46: 758-62.
21. 18F-FDG accumulations in the gastrointestinal tract in PET/CT: correlation with endoscopic and histopathologic results. J Nucl Med 2004; 45: 1804-10.
22. Antoch G, Vogt FM, Freudenberg LS et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003; 290: 3199-206.
23. Antoch G, Saoudi N, Kuehl H et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004; 22: 4357-68.
24. Bar-Shalom R, Yefremov N, Guralnik L et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003; 44: 1200-9.
25. McKenna R, Libshitz H, Mountain C et al. Roentgenographic evaluation of mediastinal lymph nodes for pre-operative assessment in lung cancer. Chest 1985; 88: 206-10.
26. Dwamena B, Sonnad S, Angobaldo J et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. Radiology 1999; 213: 530-6.
27. Lardinois D, Weder W, Hany T et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7.
28. Antoch G, Stattaus J, Nemat A et al. Non-small cell lung cancer: dual-modality PET/CT in pre-operative staging. Radiology 2003; 229: 526-33.
29. Halpern B, Schiepers C, Weber W et al. Pre-surgical staging of non-small cell lung cancer: PET, integrated PET/CT and software image fusion. Chest 2005 (in press).
30. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 2004; 45: 1640-6.
31. Zimmer L, Snyderman CH, Fukui M et al. The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear Nose Throat J 2005; 84: 108-10.
32. Branstetter BF, IV, Blodgett TM, Zimmer LA et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone? Radiology 2005; 235: 580-6.
33. Schoder H, Yeung HWD, Gonen M et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image Fusion. Radiology 2004; 231: 65-72.
34. Fueger B, Weber W, Quon A et al. Performance of 18F-FDG PET and Integrated PET/CT in Restaged Breast Cancer Patients. Mol Imaging Biol 2005 (in press).
35. 18F]fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol 2004; 6: 411-6.
36. Freudenberg LS, Antoch G, Schutt P et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325-9.
37. Bar-Shalom R, Guralnik L, Tsalic M et al. The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 2005 (in press).
38. 18F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 2003; 44: 1797-803.
39. Kamel IR, Cohade C, Neyman E et al. Incremental value of CT in PET/CT of patients with colorectal carcinoma. Abdominal Imaging 2004; 29: 663-8.
40. 18F-FDG PET, In-Line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med 2005; 46: 587-95.
41. Even-Sapir E, Parag Y, Lerman H et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 2004; 232: 815-22.
42. Selzner M, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 1027-36.
43. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39: 2012-20.
44. Goerres GW, Stupp R, Barghouth G et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005; 32: 153-62.
45. Antoch G, Kanja J, Bauer S et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45: 357-65.